Lee McCracken

Oct 28, 2015

Molecular Diagnostics has appointed Lee McCracken to its board of directors. In 2014, McCracken was appointed CEO of Gensignia Life Sciences. Previously, he held positons as president and CEO of Pathwork Diagnostics. Before that, McCracken served as corporate head of business development at Prometheus Laboratories, senior vice president of pharma business development at Diversa (merged with Verenium), president and chief business officer of GenStar Therapeutics, and senior vice president of corporate development at CombiChem (acquired by DuPont Pharmaceuticals).

Lee McCracken

CARB-X Grants Melio $3.5M for Neonatal Sepsis Test

Major Depression Contributors Uncovered in Multi-Ancestry GWAS Meta-Analysis

NeoGenomics, Adaptive Biotech Partner to Offer Combined Blood Cancer Testing

JP Morgan Healthcare Conference, Day 1: Oxford Nanopore, 10x Genomics, Bruker, Qiagen, More

Preliminary Earnings Roundup: Quanterix, Pacific Biosciences, Illumina